Literature DB >> 24118625

Association of vascular access type with inflammatory marker levels in maintenance hemodialysis patients.

Ramanath Dukkipati1, Miklos Z Molnar, Jongha Park, Jennie Jing, Csaba P Kovesdy, Raahil Kajani, Kamyar Kalantar-Zadeh.   

Abstract

Aggressive NIH is a common histopathological lesion found at the sites of venous stenosis in arteriovenous fistula (AVF) and arteriovenous grafts (AVG). Inflammatory mediators have been proposed to play a pathogenic role in NIH, but there is paucity of data evaluating this hypothesis in clinical studies or in animal models. Serum levels of inflammatory mediators can potentially identify patients at high risk of AVF and AVG dysfunction. In a cross-sectional cohort study of 754 HD patients who were part of the NIED study cohort, we examined the associations between inflammatory markers including serum interleukin (IL) 1β, IL-6, C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α) and type of vascular access. Unadjusted and multivariate-adjusted linear regression models were used. In addition, time-dependent regression model was used to assess the association between inflammatory markers and mortality. We observed that in the multivariate-adjusted model, inflammatory mediators interleukin-6 (IL-6), interleukin-1L-ß (IL-1ß), and C-reactive protein (CRP), the predicted value in hemodialysis patients, are lowest in patients with AVF and highest in central venous catheter (CVC) and AVG even in case-mix and malnutrition-inflammation complex syndrome (MICS)-adjusted models. IL-6 and CRP levels fall consistently in the same patients when AVG or CVC is changed to AVF and increase if the same patient changes access from AVF to AVG or CVC. Obesity is a risk factor for fistula failure and fistulas are associated with the lowest mortality compared with CVC and AVG. We did not find any statistically significant association between tumor necrosis factor-α (TNF- α) and vascular access outcomes. Higher levels of inflammatory mediators seen in CVC and AVG compared with AVF could potentially explain the higher mortality seen in patients with CVC and AVG compared with AVF.
© 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24118625     DOI: 10.1111/sdi.12146

Source DB:  PubMed          Journal:  Semin Dial        ISSN: 0894-0959            Impact factor:   3.455


  10 in total

1.  C-reactive protein variability is associated with vascular access outcome in hemodialysis patients.

Authors:  Wei-Hung Kuo; Yueh-Ting Lee; Hwee-Yeong Ng; Chun-Yeh Wang; Chien-Hsing Wu; Chien-Te Lee
Journal:  J Clin Lab Anal       Date:  2017-04-27       Impact factor: 2.352

2.  CD4(+) lymphocytes improve venous blood flow in experimental arteriovenous fistulae.

Authors:  Juan C Duque; Laisel Martinez; Annia Mesa; Yuntao Wei; Marwan Tabbara; Loay H Salman; Roberto I Vazquez-Padron
Journal:  Surgery       Date:  2015-05-18       Impact factor: 3.982

3.  Vascular Access Type and Clinical Outcomes among Elderly Patients on Hemodialysis.

Authors:  Timmy Lee; Mae Thamer; Qian Zhang; Yi Zhang; Michael Allon
Journal:  Clin J Am Soc Nephrol       Date:  2017-08-10       Impact factor: 8.237

4.  Tracking and Therapeutic Value of Human Adipose Tissue-derived Mesenchymal Stem Cell Transplantation in Reducing Venous Neointimal Hyperplasia Associated with Arteriovenous Fistula.

Authors:  Binxia Yang; Akshaar Brahmbhatt; Evelyn Nieves Torres; Brian Thielen; Deborah L McCall; Sean Engel; Aditya Bansal; Mukesh K Pandey; Allan B Dietz; Edward B Leof; Timothy R DeGrado; Debabrata Mukhopadhyay; Sanjay Misra
Journal:  Radiology       Date:  2015-11-19       Impact factor: 11.105

5.  Aortic Arch Calcification Predicts Patency Loss of Arteriovenous Fistula in End-Stage Renal Disease Patients.

Authors:  Yit-Sheung Yap; Kai-Ting Ting; Wen-Che Chi; Cheng-Hao Lin; Yi-Chun Liu; Wan-Long Chuang
Journal:  Sci Rep       Date:  2016-04-22       Impact factor: 4.379

6.  Maturation of arteriovenous fistulas in patients with and without preexisting hemodialysis catheters.

Authors:  Yuthapong Wongmahisorn
Journal:  Ann Med Surg (Lond)       Date:  2019-10-11

Review 7.  Understanding Development of Malnutrition in Hemodialysis Patients: A Narrative Review.

Authors:  Sharmela Sahathevan; Ban-Hock Khor; Hi-Ming Ng; Abdul Halim Abdul Gafor; Zulfitri Azuan Mat Daud; Denise Mafra; Tilakavati Karupaiah
Journal:  Nutrients       Date:  2020-10-15       Impact factor: 5.717

8.  Evaluation of Safety for Scanning Carbon-Ion Radiotherapy in Hemodialysis Patients With Prostate Cancer.

Authors:  Yosuke Takakusagi; Makito Suga; Yohsuke Kusano; Kio Kano; Satoshi Shima; Keisuke Tsuchida; Nobutaka Mizoguchi; Itsuko Serizawa; Daisaku Yoshida; Tadashi Kamada; Shinichi Minohara; Hiroyuki Katoh
Journal:  Cureus       Date:  2022-02-14

9.  Antiplatelet agents maintain arteriovenous fistula and graft function in patients receiving hemodialysis: A nationwide case-control study.

Authors:  Yung-Ho Hsu; Yu-Chun Yen; Yi-Chun Lin; Li-Chin Sung
Journal:  PLoS One       Date:  2018-10-18       Impact factor: 3.240

10.  ESR, CRP, and failure of Arterio-Venous Fistula (AVF).

Authors:  Morteza Khavanin Zadeh; Zahra Omrani; Roozbeh Cheraghali; Mehdi Hashemaghaee
Journal:  Med J Islam Repub Iran       Date:  2021-09-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.